Physician profile
Brian P Hauser
NPI 1982674438
$2,905.91
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $315 · 2021: $122 · 2022: $793 · 2023: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $841.24 | 2019-2023 | Farxiga, Breztri |
| Pfizer INC. | $352.14 | 2019-2023 | |
| Abbvie INC. | $311.07 | 2022-2023 | |
| Amgen INC. | $150.47 | 2019 | |
| Glaxosmithkline, LLC. | $138.31 | 2019-2022 | |
| Sanofi Pasteur INC. | $122.81 | 2019-2020 | |
| Novo Nordisk INC | $97.94 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $83.63 | 2019-2023 | Lithoclast |
| Antares Pharma, INC. | $73.88 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Janssen Pharmaceuticals, INC | $73.01 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $68.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $66.63 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $60.42 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.90 | 2022-2023 | Jardiance |
| Lilly USA, LLC | $48.37 | 2022-2023 | Mounjaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.49 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.30 | 2022 | |
| Lucid Diagnostics INC. | $30.75 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.59 | 2022-2023 | Xifaxan |
| Exeltis, USA INC. | $27.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.30 | 2019 | |
| Allergan, INC. | $18.04 | 2020 | |
| Halozyme INC | $15.39 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $14.61 | 2023 | Quviviq |
| Corium, LLC | $13.81 | 2023 | Azstarys |
| Abbott Laboratories | $13.24 | 2023 | Proclaim |
| Organon LLC | $12.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.61 | 2019 | |
| Therapeuticsmd, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.